(Q37839071)

24 August 2017

1 reference

title

Posaconazole: a pharmacoeconomic review of its use in the prophylaxis of invasive fungal disease in immunocompromised hosts (English)

1 reference

Katherine A Lyseng-Williamson

24 August 2017

author

series ordinal

1

object named as

Katherine A Lyseng-Williamson

1 reference

24 August 2017

publication date

1 March 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

29

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

251-268

1 reference

Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11206800-000000000-00000

Invasive fungal infections: the challenge continues

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206800-000000000-00000

Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206800-000000000-00000

Patients at high risk of invasive fungal infections: when and how to treat

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206800-000000000-00000

Changing epidemiology of rare mould infections: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206800-000000000-00000

Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206800-000000000-00000

Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206800-000000000-00000

Posaconazole : a review of its use in the prophylaxis of invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206800-000000000-00000

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206800-000000000-00000

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206800-000000000-00000

Cost-effectiveness of posaconazole compared with standard azole therapy for prevention of invasive fungal infections in patients at high risk in Switzerland

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206800-000000000-00000

Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206800-000000000-00000

Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206800-000000000-00000

Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206800-000000000-00000

Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206800-000000000-00000

Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206800-000000000-00000

Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206800-000000000-00000

Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206800-000000000-00000

European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21309616

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Economic evaluation of posaconazole in prophylaxis of invasive fungal infections in Italian neutropenic patients with acute myeloid leukaemia or myelodysplastic syndrome

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21309616

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21309616

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2165/11206800-000000000-00000

1 reference

Dimensions Publication ID

24 August 2017

1020481432

0 references

1 reference